The DHF, DMR, DHR, EU MDR Technical Documentation Similarities, Differences and The Future (April 28, 2023)
06 avr. 2023 09h38 HE
|
Research and Markets
Dublin, April 06, 2023 (GLOBE NEWSWIRE) -- The "The DHF, DMR, DHR, EU MDR Technical Documentation Similarities, Differences and The Future" training has been added to ResearchAndMarkets.com's...
Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions Training Course (April 19-20, 2023)
31 mars 2023 07h43 HE
|
Research and Markets
Dublin, March 31, 2023 (GLOBE NEWSWIRE) -- The "Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions Training Course" training has been added to ...
cGMP Regulatory Inspections Webinar: Key Areas of How ICH Q7 was Established - Through the Eyes of FDA, EMA and PMDA
28 mars 2023 10h38 HE
|
Research and Markets
Dublin, March 28, 2023 (GLOBE NEWSWIRE) -- The "cGMP Regulatory Inspections - Through the Eyes of FDA, EMA and PMDA Webinar" webinar has been added to ResearchAndMarkets.com's offering. This...
2 Day Seminar: Health Canada/USP/EP Raw Material Requirements in a cGMP Environment Issues and Solutions (Philadelphia, PA, United States - March 16-17, 2023)
17 mars 2023 05h28 HE
|
Research and Markets
Dublin, March 17, 2023 (GLOBE NEWSWIRE) -- The "Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions" training has been added to ResearchAndMarkets.com's...
PharmAla Biotech Completes Annual General Meeting
01 mars 2023 08h00 HE
|
PharmAla Biotech
TORONTO, March 01, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) has completed its first Annual General Meeting as a publicly-traded company. The company is happy to report that all motions...
Optimi Health Enters Australian Medical MDMA And Psilocybin Market With Mind Medicine Australia Distribution Agreement
01 mars 2023 07h30 HE
|
Optimi Health Corp.
Highlights: Signed Purchase Orders with Mind Medicine Australia to ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA (using...
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease
28 févr. 2023 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
PharmAla Biotech Closes Purchase Order With Emyria Ltd., Completes Filing of “LaNeo” Trademark in Australia
14 févr. 2023 08h00 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 14, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that, in the wake of a landmark decision by the...
Dipharma completes second phase of CGMP expansion at its Kalamazoo site
10 févr. 2023 10h29 HE
|
Dipharma Francis S.r.l
MILAN, Italy, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Dipharma Francis S.r.l. (Dipharma), a global CDMO and leading manufacturer of Active Pharmaceutical Ingredients and advanced Intermediates, announced...
One Month Remains to Register for the cGMP Regulatory Inspections Course - Through the Eyes of FDA, EMA and PMDA (March 7, 2023)
06 févr. 2023 05h43 HE
|
Research and Markets
Dublin, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The "cGMP Regulatory Inspections - Through the Eyes of FDA, EMA and PMDA" training has been added to ResearchAndMarkets.com's offering. GMP-compliance is...